Opicapone (Ongentys), an adjunctive medication for Parkinson’s disease, extends the efficacy of levodopa by inhibiting the COMT enzyme. However, its use requires strict attention to side effects and medication guidelines.

What Are the Side Effects of Opicapone (Ongentys)

Common Side Effects

Neurological Abnormalities: Dyskinesia (20%), dizziness (3%).

Gastrointestinal Reactions: Constipation (6%), dry mouth (3%).

Metabolic Abnormalities: Weight loss (4%), elevated creatine kinase (5%).

Cardiovascular Issues: Hypotension/syncope (5%), hypertension (3%).

Psychiatric Symptoms: Hallucinations (3%), insomnia (3%).

Severe Side Effects of Opicapone (Ongentys) to Watch For

Cardiovascular Risks

Manifestations: Concurrent use with COMT-metabolized drugs (e.g., epinephrine, dopamine) may cause arrhythmias and severe blood pressure fluctuations.

Management: Closely monitor heart rate and blood pressure when used in combination. Avoid co-administration with non-selective MAO inhibitors (contraindication).

Excessive Daytime Sleepiness

Risk: Patients may experience sudden onset of sleep during driving or daily activities, leading to accidents.

Recommendation: Assess history of sleep disorders before medication use. Reduce dose or discontinue if sleepiness occurs.

Impulse Control Disorders

Manifestations: Uncontrollable behaviors such as gambling, binge eating, and hypersexuality.

Management: Patients and their families should be aware of these symptoms; seek medical attention immediately if they occur.

Neuropsychiatric Symptoms

Hallucinations/Psychosis: 3% of patients experience hallucinations or delusions; discontinue medication if severe.

Neuroleptic Malignant Syndrome: Sudden discontinuation may cause high fever and muscle rigidity. Gradually reduce the dose and monitor closely.

Effects on Liver and Kidney Function

Hepatic Impairment: Dose adjustment is required for patients with moderate to severe hepatic impairment (Child-Pugh B: 25mg/day; Child-Pugh C: contraindicated).

Renal Impairment: Avoid use in patients with end-stage renal disease.

Precautions for Opicapone (Ongentys) Use

Correct Administration Method

Dose: The recommended dose is 50mg once daily, taken orally before bedtime; reduce to 25mg/day for patients with moderate hepatic impairment.

Dietary Restrictions: Fasting for 1 hour before and after taking the medication to avoid affecting absorption.

Contraindications and Drug Interactions

Absolute Contraindications: Contraindicated in patients taking non-selective MAO inhibitors (e.g., phenelzine) and those with pheochromocytoma.

Drugs to Use with Caution: Sympathomimetic drugs (e.g., albuterol) may exacerbate cardiovascular side effects.

Key Patient Education Points

Avoid Sudden Discontinuation: Gradually reduce the dose under medical guidance.

Regular Monitoring: Periodically monitor blood pressure, liver function, and psychiatric symptoms.

Immediate Medical Attention: Seek medical help promptly if palpitations, hallucinations, or behavioral abnormalities occur.